Who are PRA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eraxis, Mycamine, Cancidas, Eraxis (anidulafungin), caspofungin antifungal therapy, FK463.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pra.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

PRA — Competitive Intelligence Brief

PRA (PRA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Echinocandin antifungal. Area: Infectious Disease.

marketed Echinocandin antifungal β-1,3-glucan synthase (FKS) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

PRA (PRA) — Scynexis, Inc.. PRA (prasifungin) is an antifungal agent that inhibits fungal cell wall synthesis by targeting glucan synthase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PRA TARGET	PRA	Scynexis, Inc.	marketed	Echinocandin antifungal	β-1,3-glucan synthase (FKS)
Eraxis	ANIDULAFUNGIN	Vicuron Holdings	marketed	Echinocandin Antifungal [EPC]		2006-01-01
Mycamine	MICAFUNGIN	Teva Pharms Usa Inc	marketed	Echinocandin Antifungal	ATP-binding cassette sub-family G member 2	2005-01-01
Cancidas	CASPOFUNGIN	Merck & Co.	marketed	Echinocandin Antifungal	ATP-binding cassette sub-family G member 2	2001-01-01
Eraxis (anidulafungin)	Eraxis (anidulafungin)	Pfizer	marketed	Echinocandin antifungal	1,3-beta-D-glucan synthase
caspofungin antifungal therapy	caspofungin antifungal therapy	Centre Hospitalier Universitaire, Amiens	phase 3	Echinocandin antifungal	Beta-1,3-D-glucan synthase
FK463	FK463	Astellas Pharma Inc	phase 3	Echinocandin antifungal	1,3-β-D-glucan synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Echinocandin antifungal class)

Astellas Pharma Inc · 2 drugs in this class
Pfizer · 2 drugs in this class
Centre Hospitalier Universitaire, Amiens · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Mundipharma Research Limited · 1 drug in this class
Scynexis, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PRA — Competitive Intelligence Brief. https://druglandscape.com/ci/pra. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab